C-reactive protein (CRP) is a well-known biomarker of systemic inflammation and cardiovascular disease. We investigated the trends in prevalence of elevated CRP levels (>3.0 mg/L) in a general population of US adults. Data from 27,214 subjects aged ≥20 years in the 1999-2010 National Health and Nutrition Examination Survey were analyzed. After adjustment for age, sex, race/ethnicity, body mass index (weight (kg)/height (m) 2 ), and medications for lowering blood pressure, glucose, and lipids, the prevalence of elevated CRP decreased significantly from 36.7% in 1999-2002 to 32.0% in 2007-2010, corresponding to a decrease in mean CRP level from 1.92 to 1.66 mg/L (both P < 0.001). The trend remained significant after additional adjustment for several traditional cardiovascular risk factors and use of different medications, including statins. However, the decreasing trends were attenuated after additional adjustment for total bilirubin (P = 0.08 and 0.02), which increased from 0.62 to 0.73 mg/dL over 12 years (P < 0.001). The decreasing trend of CRP levels is encouraging and may be related to the increase in total bilirubin levels. Such trends may be explained in part by the increasing use of medications such as statins, which can increase bilirubin levels and decrease CRP levels.
C-reactive protein (CRP) is a well-known nonspecific biomarker of systemic inflammation that appears to be linked to the development of cardiovascular diseases (1) . Circulating levels of CRP are elevated in persons with obesity, inflammation, insulin resistance, endothelial dysfunction, and subclinical atherosclerosis (2) (3) (4) . Prospective studies have also demonstrated that elevated circulating CRP levels predict deterioration of glycemia, incident cardiovascular disease, and mortality (5) (6) (7) (8) (9) (10) (11) (12) (13) . CRP also adds prognostic information to that conveyed by the classical Framingham risk score for incident cardiovascular events (14) .
The recently completed trial, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), has suggested that lowering CRP levels by using statin medication in asymptomatic subjects can reduce myocardial infarction, stroke, and total mortality rate even in subjects with elevated CRP levels but no hyperlipidemia (15, 16) ; however, the causal role of CRP in cardiovascular disease and related risk factors is still controversial (17) . Nevertheless, the clinical utility of CRP as a biomarker for monitoring cardiovascular risk is well recognized. A previous review has even suggested CRP level as a potential target for therapy (18) . In this regard, a recent study has suggested the use of age and CRP level as a simple method to identify subjects at high cardiovascular risk (19) . Moreover, the measurement of CRP has recently been recommended in Canada for all patients with intermediate cardiovascular risk (20) . Therefore, it is important to investigate CRP levels at a population level to identify the proportion of persons who are at high risk of cardiovascular disease or related outcomes according to the measurement of CRP level. However, to the best of our knowledge, there has been no report on recent trends in the prevalence of elevated CRP or mean CRP levels in a national survey study. Therefore, we investigated the 12-year trends in the prevalence of elevated CRP levels, as well as mean CRP level, in a general nationally representative noninstitutionalized population of US adults during 1999-2010.
MATERIALS AND METHODS

Study subjects
The 1999-2010 National Health and Nutrition Examination Survey (NHANES) was conducted by the National Center for Health Statistics of the US Centers for Disease Control and Prevention (Atlanta, Georgia) as a continuous cross-sectional survey of the health and nutritional status of the civilian, noninstitutionalized US population (21) . In 1999, the survey became a continuous program and examined a nationally representative sample of about 5,000 persons each year. Data are released for every 2-year cycle, and the detailed measurement procedures and protocols have been described on the website of the National Center for Health Statistics (21) . All participants gave informed consent, and the study received approval from the Centers for Disease Control and Prevention's institutional review board. Data from the 1999-2010 NHANES include 30,752 subjects aged ≥20 years who were both interviewed and examined in the mobile examination center. After the exclusion of pregnant women and subjects with missing data on CRP levels and body mass index (weight (kg)/height (m) 2 ), there were 27,214 subjects included in our analysis.
CRP measurement methods
CRP levels were measured by latex-enhanced nephelometry with high sensitivity by using a Dade Behring Nephelometer II Analyzer System (Dade Behring Diagnostics, Inc., Somerville, New Jersey). The standards of the assays were prepared by Dade Behring Diagnostics and standardized against the World Health Organization's International Reference Preparation of CRP serum (21) . The measurement was performed by the Immunology Division, Department of Laboratory Medicine, University of Washington Medical Center, and there were no changes to equipment, laboratory measurement methods, or laboratory site during the 12-year period (21 [2009] [2010] , a level equal to the limit of detection divided by the square root of 2 was imputed. Two or 3 levels of quality control were purchased from BioRad Laboratoties, Inc. (Hercules, California) or were prepared in the laboratory. These quality controls with CRP levels spanning from the borderline and high range values were run for each test series. New controls were purchased or prepared in sufficient quantity to provide quality control for 2 years and were analyzed for at least 20 runs in parallel with the current controls. Data from these quality controls were then used to estimate any methodological imprecision and to assess the magnitude of any time-associated trends. The coefficients of variation that used different lots of CRP quality controls were all <10% in each of the 6 two-year survey periods. Details of sample collection, measurement procedures, quality control, and quality assurance have been described elsewhere (21) . An elevated CRP level was defined as >3.0 mg/L (1).
Prescription medications
The use of prescription medications for lowering blood lipids, glucose, and blood pressure, as well as the use of aspirin or clopidogrel in the past month, was assessed by questionnaires. Participants were asked whether they had used any prescription medicine in the past month, and participants showed the interviewer the medication containers and the exact names of all the products they had used. If the container was unavailable, the interviewer asked the participant to verbally report this information. Details on the classification of the prescription medications can be found in the Web Appendix available at http://aje.oxfordjournals.org/. A participant who took 2 or more different classes of medication for the same therapeutic use (lowering either blood lipids, glucose, or blood pressure), either as a single combination pill or several different pills, was described as having received polytherapy.
Other variables of interest
Information on race/ethnicity, education, history of cardiovascular disease, smoking, and alcohol consumption was obtained from self-reported questionnaires at baseline (21, 22) . Subjects who had smoked ≥100 cigarettes in their lives were defined as "ever" smokers. Regular alcohol drinking was defined as consumption of any type of alcoholic beverage at least once a week in the past year. The estimated glomerular filtration rate was calculated by using the modified prediction equation from the Modification of Diet in Renal Disease Study (23) . Albuminuria was defined as a urinary albumin-to-creatinine ratio ≥30 μg/mg (24) . Total bilirubin levels were measured by using a Hitachi model 917 multichannel analyzer (Boehringer Mannheim Diagnostics, Inc., Indianapolis, Indiana) in 1999-2000 with both commercial and in-house quality controls covering the normal and abnormal levels. The levels were measured by using a Beckman Synchron LX20 system in 2003-2007 and a Beckman UniCel DxC800 Synchron (Beckman Coulter, Inc., Fullerton, California) in 2008-2010 with both commercial quality controls and blind quality control specimen from NHANES. In 2001-2002, these levels were measured by using either a Hitachi model 917 multichannel analyzer or a Beckman Synchron LX20 system, and the reported values were adjusted by regression equations to allow comparison across the 2 methods. Quality controls were run in each assay with coefficients of variation <10% in all survey periods. Details on the laboratory measurement methods of other biochemical variables can be found in the Web Appendix and elsewhere (21) . and standard error. Variables with skewed distribution are expressed as geometric mean (95% confidence interval). Examination sampling weights were used in all analyses to adjust for nonresponse bias and the oversampling of blacks, Mexican Americans, and the elderly to obtain estimates representative of the US Census civilian noninstitutionalized population (21) . Sampling errors were estimated by using the primary sampling units and strata provided in the data set. Because serum triglycerides and low-density lipoprotein cholesterol were measured only in subjects who were examined in the morning sessions and who had fasted for 8-24 hours, separate fasting weights were used for the analysis of these variables. To obtain more reliable estimates, we combined data from 2 survey cycles to produce estimates for The P values for interaction were estimated by including each multiplicative interaction term in the regression models in the full sample after adjusting for the main effects of the covariates. In a separate analysis, results were presented after excluding subjects with CRP levels >10 mg/L, which may reflect acute inflammation (1). A 2-tailed P < 0.05 was considered statistically significant. Table 1 shows the trends in clinical characteristics and cardiovascular risk factors from 1999-2002 to 2007-2010. During 1999-2010, there were significant increases in age, body mass index, educational level, glycosylated hemoglobin, high-density lipoprotein cholesterol, estimated glomerular filtration rate, and total bilirubin, as well as in the percentages of nonsmokers and regular alcohol drinkers (all adjusted P < 0.05). There were also significant decreases in total cholesterol, low-density lipoprotein cholesterol, triglycerides, blood pressure, alkaline phosphatase, aspartate aminotransferase, γ-glutamyltransferase, and the prevalence of albuminuria (all adjusted P < 0.001). Overall, 56.6% (standard error, 0.6%) of the subjects reported the use of any prescription medication in the past month. Among them, 76.9% (standard error, 0.6%) showed the interviewer all the medication containers, 7.4% (standard error, 0.3%) showed some but not all containers, and 15.7% (standard error, 0.5%) reported this information verbally only. As shown in Table 1 , the use of medications for lowering blood pressure, glucose, and lipids also increased significantly (all adjusted P < 0.001). The use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, β-blockers, diuretics, metformin, thiazolidinediones, insulin, statins, nicotinic acid, and cholesterol adsorption inhibitors increased significantly. Table 2 shows the clinical characteristics according to different CRP levels. As expected, CRP levels correlated positively with age, body mass index, glycosylated hemoglobin, total cholesterol, low-density lipoprotein cholesterol, triglycerides, systolic blood pressure, alkaline phosphatase, alanine aminotransferase, and γ-glutamyltransferase and negatively Table 2 . with high-density lipoprotein cholesterol, estimated glomerular filtration rate, and total bilirubin (all adjusted P < 0.01). Subjects with elevated CRP levels tended to be women, less educated, and smokers and were more likely to be nonHispanic black or Mexican American (all adjusted P < 0.01).
RESULTS
Continued
The percentages of subjects with albuminuria and a history of previous diagnosis of cardiovascular disease were higher among subjects with elevated CRP levels (all adjusted P < 0.01). The percentage of subjects taking calcium channel blockers, β-blockers, diuretics, thiazolidinediones, insulin, statins, and cholesterol adsorption inhibitors was also higher among subjects with elevated CRP levels (all adjusted P < 0.05).
As shown in Table 3 , the prevalence of elevated CRP decreased significantly from 36. The decrease in CRP levels was greater in subjects with higher age and in non-Hispanic whites (both P for interaction < 0.05, Table 3 ). In a separate analysis, similar trends were observed after excluding subjects with CRP levels >10 mg/L (Web Table 1 ). As shown in Web Table 2 , subjects of higher age and non-Hispanic whites tended to have larger increases in the use of any lipid-lowering medication, especially statins, compared with subjects with lower age and those in other racial/ethnic groups (all P for interaction < 0.05).
As shown in Table 4 , the decreases in the prevalence of elevated CRP and mean CRP levels remained significant (both P < 0.001) after adjusting for age, sex, race/ethnicity, body mass index, and other characteristics that changed significantly over the 12-year period, but not total bilirubin. After further adjustment for total bilirubin levels, the decreasing trend in the prevalence of both elevated and mean CRP levels was attenuated (P = 0.076 and 0.024, respectively), although that of mean CRP level still remained significant. Similar trends were observed after excluding subjects with CRP levels >10 mg/L (Web Table 3 ). Replacement of individual medications for lowering blood pressure, glucose, and lipids and their polytherapies by the use of any blood pressure-, glucose-, and lipid-lowering medication in the adjustment models resulted in similar findings (Web Table 4 ). Because statin medications were the most commonly used (Table 2) , we investigated whether the change in CRP or total bilirubin levels was related to statin use. As shown in Web Table 5 , the change in mean CRP level, but not total bilirubin level, was significantly larger in subjects taking statins (P for interaction = 0.005), although the difference in the change in prevalence of elevated CRP levels between subjects who were and were not taking statins did not reach statistical significance (P for interaction = 0.11).
Among subjects who did not take aspirin, clopidogrel, or any medication for lowering blood pressure, glucose, or lipids, the trends of decreasing CRP levels and increasing total bilirubin levels over time remained significant (all P < 0.001, Web Table 6 ).
DISCUSSION
This first report of the recent trend in CRP levels in a nationally representative population of US adults shows a significant decreasing trend in CRP levels over a 12-year period. CRP is a well-known nonspecific biomarker of systemic inflammation, and our study suggests that the decreasing trend could represent a significant improvement in the systemic inflammation status in US adults at the population level. Therefore, if the Cardiovascular Inflammation Reduction Trial (25) can show a direct effect of lowering CRP levels on the reduction of risk for myocardial infarction, stroke, and cardiovascular death, we may expect a future reduction in CRP or systemic inflammation-related cardiovascular complications and mortality.
The reasons for decreasing CRP levels over time are unclear. As shown in this and earlier studies, elevated CRP levels are associated with other cardiovascular risk factors, such as aging, obesity, low educational level, smoking, history of cardiovascular disease, hyperglycemia, elevated blood pressure, dyslipidemia, renal dysfunction, and liver damage. A recent NHANES study showed no significant change in body mass index or obesity prevalence in US adults from 2003-2004 to 2009-2010 (26) , whereas other NHANES studies have demonstrated an improvement in the control of hypertension, diabetes, and hypercholesterolemia among US adults (27) (28) (29) (30) (31) (32) . In our study, the decrease in the prevalence of elevated or mean CRP levels remained significant after adjusting for these potential confounding factors, suggesting that there may be unidentified factors that contribute to the observed decrease in CRP levels. However, the decreasing trend was attenuated substantially after additional adjustment for total bilirubin levels. Therefore, the decreasing trend in CRP levels over the 12-year period could be related at least partly to the change in total bilirubin levels.
Bilirubin has antioxidant and antiinflammatory properties and has been identified as a potential biomarker for cardiovascular risk (33) . This may account for its inverse correlation with CRP levels (34) . In our study, we found an increasing trend of the use of some blood pressure-, glucose-, and lipid-lowering medications over the 12-year period. Lipid-lowering medications such as statins can reduce CRP levels (35) . Moreover, statins have been shown to activate heme oxygenase-1, which may account for their antiinflammatory and antiproliferative effects (36) . As heme oxygenase-1 plays a role in the degradation of heme to biliverdin, carbon monoxide, and ferritin, and biliverdin is converted to bilirubin by the enzyme biliverdin reductase (37), subjects taking statins may have higher total bilirubin levels (38) . Therefore, total bilirubin levels may be used as a surrogate marker for the statin dosage.
Although the decreasing trend in CRP levels was significant in subjects who were and were not taking statins, the decrease in CRP levels was larger in subjects taking statins. Abbreviations: CI, confidence interval; CRP, C-reactive protein; NHANES, National Health and Nutrition Examination Survey; SE, standard error. *P < 0.05, **P < 0.01, and ***P < 0. Moreover, the percentage of subjects taking statins nearly doubled from 8.4% to 16.0% over the 12-year period. Therefore, the changes in total bilirubin and CRP levels could be explained at least in part by the increasing use of statins. Besides statins, other drugs such as aspirin, clopidogrel, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors have also been reported in some studies to have CRP-lowering effects in subjects at high cardiovascular risk (39) (40) (41) (42) . Their increasing use could also contribute to the decreasing trend in CRP levels. Although the decreasing trend in CRP levels did not attenuate after additional adjustment for the use of different medications, the significant decrease in CRP levels with time in the fully adjusted model could be due to some residual confounding effects and the lack of data on the dosage of each medication. Besides the increasing use of prescription medications, the improvement over the 12-year period of cardiovascular risk factors such as education, smoking, lipids, blood pressure, renal function, and some liver function markers may also contribute to the observed decreasing trend in CRP levels. NHANES 1999-2010 is a continuous survey program, and this provides a good opportunity to study trends in the prevalence of elevated CRP levels or mean CRP levels in the recent 12-year period from 1999-2000 to 2009-2010, especially because there were no changes to the equipment, laboratory measurement methods, or laboratory site (21) . Our study has the strengths of a large sample size, good sampling design, and good quality control, allowing us to obtain nationally representative estimates. However, this study has several limitations. We could not exclude the possibility that the observed decreasing trend in CRP levels could be caused by a downward assay drift, because assay drift was monitored within each survey period but not across different survey periods. This could have exaggerated the CRP trend. Nevertheless, the observed trend remained significant when we excluded the first or last 4-year period, suggesting that it was unlikely to be caused by large drift at either end of the study period. Because the sample size of this study is very large, the significance of the trends in some subgroups and some interaction terms could be misleading because of the high power to detect small differences and associations. Moreover, the lack of data on the dosage of the prescription medications and on rheumatological conditions is also a limitation of this study.
In conclusion, there was a decreasing trend of CRP levels in US adults over the 12-year study period, which may represent an improvement in systemic inflammation at the population level. This decrease in CRP levels may be related to an increase in total bilirubin levels in the same period. Such trends may be explained, at least in part, by increasing use of medications, such as statins, which have been shown to raise total bilirubin while decreasing CRP levels.
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